Glucose degradation products in PD fluids: Do they disappear from the peritoneal cavity and enter the systemic circulation?  by Zeier, Martin et al.
Kidney International, Vol. 63 (2003), pp. 298–305
Glucose degradation products in PD fluids: Do they disappear
from the peritoneal cavity and enter the systemic circulation?
MARTIN ZEIER, VEDAT SCHWENGER, REINHOLD DEPPISCH, ULRIKE HAUG, KAI WEIGEL,
U. BAHNER, CHRISTOPH WANNER, H. SCHNEIDER, THOMAS HENLE, and EBERHARD RITZ
Department of Internal Medicine, University of Heidelberg, Heidelberg; Gambro Corporate Research, Hechingen;
Technical University of Dresden, Institute of Food Chemistry, Dresden; Nephrology Department, University of Wu¨rzburg,
Wu¨rzburg; and Nephrology Center, Stuttgart, Germany
Third, plasma fluorescence (exc. 350/em. 430 nm) as an indexGlucose degradation products in PD fluids: Do they disappear
of circulating AGE compounds as well as plasma CML concen-from the peritoneal cavity and enter the systemic circulation?
trations were significantly higher in the conventional PD fluidBackground. Glucose degradation products (GDP) are gen-
period versus low GDP PD fluid period. Fourth, CA 125 con-erated in peritoneal dialysis (PD) fluid during heat sterilization
centrations in spent dialysate were higher during the low GDPand storage. They are thought to adversely affect the peritoneal
PD fluid period compared to the conventional PD fluid period.membrane. The fate of GDP within the peritoneal cavity has
Conclusion. Conventional PD fluid undergoes modificationsnot been well characterized.
during intraperitoneal dwell with a loss of AGE forming capac-Methods. A clinical study was designed to determine (1)
ity, suggesting breakdown, precipitation or resorption of GDPwhether during the dwell in the peritoneal cavity GDP concen-
in vivo. This is accompanied by an increase in plasma AGEtration decreases in the PD fluid as assessed by ex vivo forma-
compounds.tion of AGE; (2) whether exposure to GDP-containing PD
fluids increases plasma fluorescence (as an index of plasma
AGE concentration) as well as plasma carboxymethyllysine
(CML) concentration; and (3) whether exposure to GDP-con-
Glucose as a highly reactive substance is easily degradedtaining PD fluids adversely affects glycoprotein CA 125 concen-
into glucose degradation products (GDP), which are toxictration. A two-group crossover design was adopted comprising
two consecutive observation periods of eight weeks each. Sta- [1, 2] and can give rise to early or advanced glycation
ble PD patients were exposed in random order either to con- end products (AGE) [3, 4]. The formation of GDP is de-
ventional PD fluid (heat sterilized at pH 5.5) and subsequently pendent on pH, temperature and time. In peritonealto PD test fluid (or the 2 fluids in reverse order). The PD test fluid
dialysis (PD) fluids GDP are generated when glucose iswas sterilized using a multicompartment bag system separating
heated under acidic conditions [5] as well as subsequentlyhighly concentrated glucose at pH 3 from the buffer solution.
Conventional and test fluids differed with respect to concentra- during storage of the sterilized fluids. The GDP comprise
tions of GDP, that is, 3-deoxyglucosone (118 vs. 12.3 mol/L), formaldehyde, glyoxal, methylglyoxal, 3-deoxyglucosone,
methylglyoxal (5.3 mol/L vs. below detection threshold), 3, 3,4-dideoxyglucosone-3-ene, and many substances that4-dideoxyglucosone-3-ene (10mol/L vs. below detection thresh-
have not yet been identified chemically [6].old) and acetaldehyde (226 vs. 1 mol/L).
The reactions that GDP (i.e., carbonyl compounds) un-Results. The following results were obtained. First, meth-
ylglyoxal disappeared completely as early as two hours after dergo in the peritoneal cavity and the benefit potentially
intraperitoneal instillation of conventional PD fluid. Second, derived from elimination of GDP are of great clinical
when spent conventional dialysate was recovered after a two interest. Initial studies [7, 8] show higher glycoproteinhour and particularly an eight hour dwell and subsequently
CA 125 concentrations as an index of mesothelial cellincubated ex vivo with 40 mg of human serum albumin, there
number and/or viability [9, 10] when low GDP PD fluidswas a continuous decrease of AGE-forming capacity, that is,
less generation of fluorescence (AGE) and pyrraline (non- are used.
fluorescent Amadori product), and an increase of advanced It was the purpose of the present prospective random-
oxidation protein products (AOPP) in the spent dialysate. ized, crossover study to confirm and extend these results
by addressing two issues:
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ucts (AOPP) in spent PD dialysates as an index of old in group B (5 males, 1 female). The time on CAPD
was not significantly different (median 33 months, rangeGDP dependent glycation and oxidation capacity.
2. Do GDP escape from the peritoneal cavity and 3 to 93 in group A vs. 10 months, range 2 to 30 in group
B). Patients used 1.5% glucose, 2.5% glucose or 4% glu-enter the systemic circulation? Plasma fluorescence,
total and molecular weight-specific, as well as car- cose containing PD fluids as required for the purpose of
ultrafiltration.boxymethyllysine (CML) concentrations were com-
pared during the treatment periods using conven-
Sampling of study materialtional and low GDP PD fluids, respectively.
Fifty milliliter samples of spent dialysate after short
(2 hour) or overnight (8 hour) dwell were collected and
METHODS
immediately (30 min) centrifuged at 2000  g for 10
Study design minutes before freezing the supernatant at 70C for
later analysis. Samples were thawed no more than once.The study was performed as a multicentric, prospec-
tive, randomized, two-group crossover clinical trial com- The same procedure was adopted for the ethylenedi-
aminetetraacetic acid (EDTA) blood samples.prising two consecutive observation periods of eight
weeks each.
Analytical techniquesIn random order patients were either first exposed to
PD fluid with minimal concentrations of glucose degra- Quantitation of methylglyoxal in PD fluid. Methyl-
glyoxal was quantitated using a reverse phase C18 high-dation products (low GDP fluid, Gambrosol trio; Gam-
bro Co., www.gambro.de) during eight weeks and subse- pressure liquid chromatography (HPLC) method ac-
cording to Nilsson-Thorell et al [11]. The detection limitquently switched to a conventional PD fluid (high GDP
fluid, Gambrosol, Gambro Co.) for the subsequent eight was 2.8 mol/L.
Ex vivo generation of AGE-specific fluorescence in per-weeks (group A). Alternatively, patients were started with
high GDP fluid and were subsequently switched to low itoneal dialysis fluid. The presence of reactive carbonyl
compounds (i.e., GDP) in the peritoneal dialysis fluidGDP fluid (group B). The 1.5% glucose-containing PD
fluids differed with respect to pH (pH5.5 in high GDP was indirectly assessed by measuring the generation of
AGE-specific fluorescence. Unused fluid and spent dialy-vs. 6.5 in low GDP fluid) and concentrations of GDP:
methylglyoxal (5.3 vs. below detection limit of 2.8mol/L), sate samples recovered after two or eight hours, respec-
tively, were adjusted to a final glucose concentration ofand acetaldehyde (226 vs. below 1 mol/L), 3-deoxy-
glucosone (118 vs. 12.3 mol/L), 3,4-dideoxyglucosone- 1.5% by addition of GDP-free glucose stock solution
(20% glucose in saline). The glucose concentration was3-ene (10 mol/L vs. below detection limit), but other-
wise had an identical composition. measured in every sample of spent PD fluid; thereafter,
nine parts of spent PD-fluid were supplemented withPatients attended the outpatient clinic at the start of
the study period and at 4, 8, 12 and 16 weeks after in- one part of the glucose stock solution and saline to yield
1.5% glucose as final concentration. Purified human se-clusion. Blood and spent dialysate samples were ob-
tained on each occasion. rum albumin was added to a final concentration of 40
mg/mL (fraction V; Sigma Co., Taufkirchen, Germany).
Study patients The latter was provided as a reactant for carbonyl com-
pound mediated protein modification. The samples wereThe study was approved by the ethics review board
of the University of Heidelberg. Stable continuous am- sterile filtered (0.02 m; Sarstedt Co., Nu¨mbrecht, Ger-
many) and incubated without any preservatives at 37Cbulatory peritoneal dialysis (CAPD) patients were in-
cluded after written informed consent. They were in- for 3 and 10 days, respectively, at neutral pH. Thereafter,
the AGE concentration was assessed as fluorescence in-cluded if they were at least 18 years old, were treated with
exchange volumes of 1500 to 2500 mL, and were able tensity (excitation 350 nm/emission 430 nm) with a spec-
trofluorometer (LS 50 B; Perkin Elmer Co., U¨berlingen,to handle a multicompartment fluid bag. Patients were
excluded if they required antibiotic treatment, suffered Germany).
To complement the group-specific fluorescent assayfrom peritonitis, or were positive for hepatitis B, C or
HIV. Overall 21 patients were randomly assigned to with quantitative chemical measurements, the concen-
tration of pyrraline as a non-fluorescent Amadori prod-study group A (N  11) or B (N  10). Fifteen patients
(9 and 6 patients in group A and B, respectively) com- uct was quantitated using HPLC after preceding enzy-
matic hydrolysis according to Henle et al [4].pleted the study. Reasons for drop out were peritonitis
(N  4), switch to hemodialysis (N  1), pain upon Assessment of advanced oxidation protein products
(AOPP). AOPP were measured according to Witko-Sar-instillation (N  1, after changing from low GDP to
conventional PD fluid). The mean age was 49  12 years sat et al [12] using albumin as a reactant. The assay was
calibrated with chloramine-T standard solutions (0 toold in group A (3 males, 6 females) and 51  8 years
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100 mol/L) after addition of potassium iodide. Genera- Repeated measures, for example, analyses at four and
eight weeks, were analyzed using analysis of variancetion of AOPP was expressed as chloramine-T equiva-
lents. (ANOVA) for repeated measures after a check for nor-
mal distribution, by the Friedman test (for paired data)Quantitation of fluorescent compounds in plasma. Flu-
orescence intensity (exc. 350 nm/em. 430 nm) in plasma or Kruskal-Wallis test (for unpaired data).
Statistical evaluation was performed using data pro-samples was quantified using a spectrofluorometer (LS
50 B; Perkin Elmer Co.). Fluorescence was also measured cessing system RS/1 (V. 6.0.1; BBN Software Products
Co., Cambridge, MA, USA).after size-selective separation of plasma protein fractions
(size exclusion chromatography, Superdex 75 HR 10/30;
Pharmacia Co., Freiburg, Germany) according to Henle
RESULTS
et al [4]. The coefficient of variation for replicate mea-
Methylglyoxal in unused and spent PD fluid:surements was 5%.
Comparison of low GDP and conventional PD fluidQuantitation of specific non-fluorescent AGE com-
pounds in plasma. Carboxymethyllysine (CML) as a non- Unused conventional PD fluid contained 5.3  1.6
mol/L methylglyoxal, while in the unused low GDPreactive AGE compound was analyzed in plasma using
an enzyme-linked immunosorbent assay (ELISA; Roche PD fluid the methylglyoxal concentration was below the
detection limit. In the 15 study patients, methylglyoxalCo., Mannheim, Germany) according to the manufactur-
er’s instructions. Prior to the analysis enzymatic protein concentration in the spent dialysate remained undetect-
able after the two and eight hour dwell during the phasedigestion was performed using proteinase K and phenyl-
methylsulfonyl fluoride (PMSF; Roche Co., Mannheim, with low GDP PD fluid. During the phase with conven-
tional PD fluid, the concentration of methylglyoxal de-Germany) according to the manufacturer’s instructions.
The intra-assay coefficient of variation was5% and the creased rapidly and was no longer detectable (2.8
mol/L) after the two or eight hour dwell, respectively.interassay CV 10%. Fructoselysine was quantified by
amino acid analysis using HPLC after prior acid hy-
Analysis of AGE-specific fluorescence, pyrralinedrolysis [4].
concentration and concentration of AOPPQuantitation of cancer antigen 125 (CA 125). The gly-
in the PD fluid after the dwellcoprotein CA 125 was analyzed in spent centrifuged dial-
ysate using a commercially available ELISA (Roche Co.) Formation of AGE. As shown in Figure 1, when un-
used low GDP PD fluid was incubated with albumin asaccording to the manufacturer’s instructions.
a reactant to generate carbonyl-mediated AGE com-
Statistical analysis pounds, very little increase in fluorescence (OD) as an
overall index of AGE formation was noted (Fig. 1A). InUnless indicated otherwise, data are given as x  SD.
The selected study design, that is, two-group crossover, contrast (Fig. 1B), when incubating unused conventional
PD fluid, a marked increase in fluorescence was notedallows the effects of treatment modalities to be analyzed
irrespective of sequence of therapy [13]. To exclude pe- that was progressive with time of incubation. Generation
of fluorescence was abrogated to a large extent whenriod and carry-over effects the data were analyzed ac-
cording to Pocock [13], that is, separately in each study spent conventional dialysate that had been recovered
after a two or eight hour dwell was used for the samegroup calculating the mean of intra-individual differ-
ences and of individual patient data means obtained dur- experiment.
The above experiments were performed with 1.5%ing the low and high GDP fluid periods. Mean values
(patient data from group A vs. group B) were compared glucose-containing PD fluids. With 2.5% glucose-con-
taining PD fluids, there was 54% higher generation ofby applying the t test for unpaired data (P 0.05 consid-
ered as significant). fluorescence (OD 109  6.9 vs. 70.6  11.7), but this
was not seen with the low GDP PD fluid.After exclusion of period and carry-over effects, data
from the two study groups could be pooled for calcula- Generation of pyrraline during incubation of low GDP
and conventional PD fluids. When unused or spent PDtion of means and standard deviation as well as for fur-
ther statistical evaluation. Data were tested for normal fluid was incubated with albumin, generation of pyrra-
line, a non-fluorescent Amadori product, was significantlydistribution by the Wilk-Shapiro test.
T test for paired and unpaired samples were applied lower with low GDP compared to conventional PD fluid,
as shown in Table 1. While the capacity to generate pyr-with normally distributed data for non-repeated mea-
sures. raline during incubation with albumin ex vivo was not
significantly modified when comparing unused fluid withWilcoxon signed-rank test for paired data and Mann-
Whitney test for unpaired data were used for data that spent dialysate after a two or eight hour dwell with low
GDP PD fluid, a significant decrease was found with con-were non-normally distributed (for non-repeated mea-
sures). ventional PD fluid.
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Fig. 1. Generation of fluorescent advanced
glycation end products (AGE) compounds
during incubation of low glucose degradation
products (GDP) and conventional peritoneal
dialysis (PD) fluids. The generation of fluo-
rescent AGE compounds is given as the per-
cent increase of optical density (excitation 350/
emission 430 nm) of unused low GDP (A;
N  6 for 1.5%, N  6 for 2.5% glucose) and
conventional (B; N  6 for 1.5%, N  6 for
2.5% glucose) PD fluid and fluid recovered
after a 2 hour [N  15 in each group (low and
high GDP)] and 8 hour [N  15 in each group
(low and high GDP] peritoneal dwell, respec-
tively. Symbols are: () unused 2.5%; ()
unused 1.5%; () spent at 2 hours; () spent
at 8 hours. For all corresponding comparisons,
that is, unused fluids and fluids from different
dwell times (2 vs. 8 hours) and ex vivo incuba-
tion times, respectively, generation of fluo-
rescence was significantly lower with low GDP
compared to conventional PD fluid (P  0.05,
paired data, Wilcoxon-test). These fluids con-
tained 1.5% glucose.
Table 1. Generation of pyrraline (pmol/mg protein) during ex vivo incubation of conventional PD fluids compared
incubation of low GDP and conventional PD fluids
to low GDP fluids (P 0.05) suggests GDP to be causallywith albumin as reactant
involved in the formation of AOPP.
Low GDP Conventional
PD fluid PD fluid Plasma fluorescence as an index of circulating AGE
Unused fluid (N  6) compounds: Comparison of the low GDP and
1.5% glucose 35.318.2a 104.028.1 conventional PD fluid periods2.5% glucose 41.212.9a 120.210.6
Spent dialysate (N  15) As shown in Figure 2, plasma fluorescence was signifi-
2 hour dwell 33.723.2a 40.526.7a cantly lower during the low GDP PD fluid period (22.18 hour dwell 41.131.0a 35.218.8a
4.1 arbitrary fluorescence intensity units  103) com-
Data are given as mean  SD.
pared to the high GDP fluid period (24.4  4.6 units a P  0.01 vs. unused conventional PD fluid (unpaired)
103) after a treatment period of four weeks. The differ-
ence was unchanged after eight weeks in the low GDP
or conventional PD fluid periods, respectively (data not
The build-up of pyrraline concentration in unused given). In 10 controls, plasma fluorescence was 5.34 
fluids was not significantly different when 1.5% and 2.5% 1.1 and in 30 HD patients 19.9  4.7 units  103 (pre-
glucose-containing fluids were used (Table 2). dialysis).
Formation of AOPP. Advanced oxidation protein Figure 3 shows the molecular weight-specific analysis
products were quantitated as chloramine-T equivalents of fluorescent AGE species in plasma. The integrated
in mol/L. When unused PD fluids were analyzed, a sig- fluorescence peaks according to molecular weight by size
nificant increase of AOPP concentration was noted after exclusion chromatography in the two study periods are
10 days of incubation versus baseline dependent on the given in the tables displayed in Figure 3.
glucose concentration (P  0.05). The same was true for A significant difference during the fourth week of the
spent low GDP PD fluid recovered after two and eight respective study period was noted between low GDP
hour dwells, respectively (Table 2). and conventional PD fluid: 533  96.9 peak area (arbi-
Despite similar generation of AOPP by unused PD trary units/104) on low GDP versus 576 85.2 on conven-
fluids at baseline, there was a significant increase of tional PD fluid (integrated fluorescence peaks, P  0.01;
AOPP in spent dialysate with dwell time (8 vs. 2 hours, Fig. 3). Representative chromatograms (patient R.P.)
P  0.05; Table 2). are given in Figure 3 to illustrate the method of peak-
Significantly higher AOPP levels of spent fluids versus specific fluorescence analysis.
unused PD fluids (P  0.05) as well as the increase of
Quantitation of the non-fluorescent AGE compoundAOPP levels over dwell period (8 vs. 2 hours) indicate
carboxymethyllysine in plasmathat the major part of AOPP was formed during the
intraperitoneal dwell. The finding of significantly higher As depicted in Figure 4, the plasma carboxymethylly-
sine concentration at baseline was 1.14  0.44 mg/L. ItAOPP concentrations at baseline as well as after 10 days
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Table 2. Formation of advanced oxidized protein products (AOPP) (mol/L) as chloramine-T equivalents at baseline
and after 10 days of in vitro incubation with albumin
Low GDP PD fluid Conventional PD fluid
10 days 10 days
Baseline ex vivo incub. Difference Baseline ex vivo incub. Difference
Unused fluid (N  6)
1.5% glucose 21.91.1 26.24.6 3.34.2 24.73.7 35.54.6a,d 10.84.9a
2.5% glucose 21.50.9 31.36.1d 9.86.0 23.41.6a 39.76.4a,d 16.36.7
Spent dialysate (N  15)
2-hour dwell 34.05.4b 39.65.5b,d 5.21.9 36.55.7a,b 45.47.9a,b,d 9.37.2
8-hour dwell 38.16.7b,c 46.07.6b,c,d 5.72.2 41.78.3b,c 49.78.3a,b,c,d 7.92.7
Data are given as mean  SD.
a P  0.05 vs. low GDP fluid (unpaired for unused PD-fluids, paired for spent PD-fluids)
b P  0.05 vs. respective unused fluid (1.5% glucose) (unpaired)
c P  0.05 vs. 2-hour dwell (paired)
d P  0.05 vs. baseline (paired)
toneal dialysates were low, but they were significantly
higher at the end of the low GDP PD fluid period. In the
group that was first exposed to conventional and subse-
quently to low GDP fluid, a rapid recovery was noted
after four weeks of low GDP fluid with no further in-
crease at eight weeks (Table 3). Conversely, in the group
where after eight weeks of treatment with low GDP fluid
the glycoprotein CA 125 concentration was 30.9  5.3
U/mL, the concentration decreased within four weeks on
conventional PD fluid to 8.9  2.2 U/mL (P  0.05).
These data refer to the eight hour dwell. The data profile
was similar but approximately 30% lower when spent
dialysate of the two hour dwell was analyzed (data not
shown).
Fig. 2. Plasma fluorescence during the low GDP and conventional PD DISCUSSION
fluid periods. Plasma fluorescence (OD 350/430 nm arbitrary units 
The above data clearly show that PD fluids with high103) is shown after a low GDP PD fluid period of 4 weeks (median 22.8)
and after a conventional PD fluid period of 4 weeks (median 24.2). Data concentrations of glucose degradation products (GDP)
are given as individual patient data and as mean  SEM. The difference generated during heat sterilization at an acidic pH arewas statistically significant (P  0.05 Wilcoxon test for paired data).
rapidly modified during two hours and particularly at
eight hours of intraperitoneal dwell. The data further
was significantly lower after eight weeks of treatment suggest that GDP disappear from the PD fluid during
with the low GDP PD fluid (1.12  0,47) compared to the dwell. This conclusion is based on measurements
eight weeks of treatment with the high GDP PD fluid of methylglyoxal as one representative GDP compound
(1.24  0.44; P  0.05). that was no longer demonstrable after a two hour dwell.
The change in CML concentration is not explained Furthermore, progressive loss of the capacity to form
as an artifact of hemoconcentration based on plasma AGE by ex vivo incubation with albumin as a reactant
albumin (baseline 39.5  3.2 g/L; 8 weeks 38.6  4.4) suggests a rapid and progressive decrease of the concen-
and hematocrit (Hct) measurements (baseline 33.5 
tration of carbonyl compounds during a peritoneal dwell.3.8%; 8 weeks 34.9  4.0%).
The study does not permit a decision about whether thisPlasma fructoselysine levels did not show any signifi-
disappearance reflects spontaneous decay, interactioncant change during the low GDP and conventional PD
with intraperitoneal molecules, particularly proteins, in-fluid periods (40.7 7.9 vs. 40.0 8.0 mg/L). The concen-
teraction with the peritoneal wall or absorption into thetrations in controls were 5.1 1.95 mg/L and in hemodi-
systemic circulation (or a combination of these possibili-alysis patients 1.61  0.5 mg/L.
ties). At any rate, the observation of higher fluorescence
Glycoprotein CA 125 concentration in supernatants of in the plasma during the period when conventional PD
spent PD fluids fluids were used is compatible with the idea that carbonyl
precursors, or AGE as their product, enter the systemicAs shown in Table 3, baseline glycoprotein CA 125
concentrations in the cell-free supernatant of spent peri- circulation. It has not been documented, and is unlikely,
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Fig. 3. Molecular weight-specific analysis of fluorescent AGE in plasma shows representative characteristic plasma fluorescence peak patterns of
patient R.P. after 4 weeks treatment with low GDP PD fluid (A) and of the same patient after 4 weeks treatment with conventional PD fluid (B).
Tables displayed at the top of the panels give the values for the mean peak areas  SD of all patients obtained after the respective study periods.
A significant difference (*P  0.05, paired data, Wilcoxon test) was found for the integrated peak area of the high-molecular-weight fraction (that
is, retention time 18.8 seconds corresponding to albumin as shown by independent calibration samples).
Table 3. Glycoprotein CA 125 (U/mL) in supernatants of spent
dialysates during the low GDP and conventional PD fluid
treatment periods (N  15)
Low GDP fluid Conventional fluid
Start of study 4 weeks 8 weeks 4 weeks 8 weeks
13.53.1 33.43.7a 31.84.1a 14.43.6 11.81.5
Data are given as mean  SEM.
a P  0.05 vs. start and conventional fluid (Wilcoxon-Wilcox)
verse transport of carbonyl compounds from the plasma
space into the peritoneal fluid, as postulated by others,
is not demonstrated in the present study. The study con-
firms previous observations [7, 8] to the extent that the
glycoprotein CA 125, an index of mesothelial cell num-
Fig. 4. Plasma carboxymethyllysine concentration during the low GDP ber and/or viability, is beneficially affected by low GDP
and conventional PD fluid periods. The concentration of carboxymeth- PD fluid. One would assume that highly reactive carbonylyllysine in plasma is seen after a low GDP PD fluid period and after a
compounds in the peritoneal cavity trigger inflammatoryconventional PD fluid period of 8 weeks each. Data are given as individ-
ual patient data and as mean  SD. The difference was statistically processes possibly mediated via nuclear factor-	B (NF-	B)
significant (P  0.05) using the t test for paired data. [14] or protein kinases, but we could not show changes
in the plasma concentration of C-reactive protein (CRP)
or other markers of microinflammation during the low
that the highly reactive GDP bind to plasma protein and GDP PD fluid period (data not shown). The periods may
are transferred intact into the plasma compartment via have been too short, however, to demonstrate such a
lymphatic absorption. The validity of the fluorescence as- benefit.
Several methodological points of the study deserve fur-say is reinforced by measurements of the specific Ama-
dori product CML, which yielded the same result. A re- ther comment. The high patient attrition rates on CAPD,
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noticed also in previous studies [8], creates definite diffi- surements of plasma fluorescence as an index of AGE
compounds. This global assay is susceptible to numerousculties as reflected by the fact that only 15 of the 21
recruited patients completed the 16 week study. A fur- artifacts. We carefully excluded artifacts from lipemia.
Patients were without infection. The only medicationsther problem is the large inter-patient variability. For
this reason, we used a prospective randomized crossover administered were phosphate binders, vitamin D prepa-
rations, and antihypertensive agents. The dose of antihy-design to deal with interindividual differences. The short-
coming of this design is that the duration of the study was pertensive agents, particularly angiotensin-converting
enzyme (ACE) inhibitors, was not changed between therestricted to the eight-week intervention period, limiting
the possibility to observe a true long-term benefit from two investigation periods. We are aware of the possibility
that the plasma AGE concentration may be affected bythe study fluid. This shortcoming was more than bal-
anced, however, by the fact that patients could be taken AGE compounds in the diet [17]. Therefore, the patients
were advised not to change the intake of nutrients withas their own controls. The consistency of the observation
was improved by repeat measurements at four and eight known high AGE content. The small increase in plasma
fluorescence was highly significant in the intra-individualweeks during the study periods. Measurements were
highly congruent at four and at eight weeks, respectively. comparisons and points to the systemic absorption of
GDP, of Amadori products or AGE compounds, respec-We also emphasize that all measurements were carried
out at least in duplicate. There is uncertainty whether CA tively. The validity of the measurement is further sup-
ported by the observation by an independent analytical125 really reflects mesothelial cell number or mesothelial
cell viability. The rapid normalization (and the reversibil- method: the fluorescence was specifically increased in a
subfraction with the molecular weight of albumin. There-ity thereof) are more in favor of the latter possibility.
This notion is also supported by the observation that the fore, a confounding effect by fluorescent low molecular
weight compounds can be excluded, a point of interest be-changes in CA 125 occurred very rapidly, for example,
in non-systematic studies within two weeks time [15]. A cause these fractions are specifically increased in uremia
as shown by Henle et al [4]. The results of the relativelypossible interference of GDP with the CA 125 measure-
ments was excluded by appropriate controls. non-specific fluorescence are confirmed by the parallel
increase in the chemically defined compound CML.The measurements of AGE and AOPP were per-
formed as group-specific global tests to assess carbonyl
What are the potential long-term consequences ofstress and accumulated oxidative stress in the effluent fluid,
our observation?respectively. As far as the AGE assay is concerned, we
emphasize that the incubation was carried out without In the past it was always assumed that high glucose was
the major culprit in the genesis of peritoneal membraneadditives, particularly without antibiotics, and in contrast
to other studies on this topic, pH was monitored to detect damage. Deterioration of peritoneal membrane charac-
teristics is to a large extent associated with new vesselpotential glucose degradation and generation of prod-
ucts impacting on pH. Because of the non-specificity of formation, that is, angiogenesis [18]. In this context it is of
interest that GDP were shown to stimulate angiogenesisthe fluorescence test for AGE, we additionally measured
the concentration of the early Amadori product pyrra- directly independent of glucose [19]. De Vriese et al docu-
mented a role of glucose in the development of perito-line that is generated by the interaction of 3-deoxygluco-
sone with 
-amino groups in general or ε-amino groups neal angiogenesis that was mediated by vascular endo-
thelial growth factor (VEGF) [20]. The relative roles ofof lysine [4]. Fluorescence and pyrraline concentrations
increased in parallel (abstract; Zeier et al, J Am Soc glucose and GDP (as well as their potential synergism)
in the stimulation of peritoneal neoangiogenesis requireNephrol 12:317A, 2001). In parallel with the decrease of
the concentration of the AGE precursor methylglyoxal, further study. Furthermore, there are numerous possibil-
ities other than neoangiogenesis for how the highly reac-the capacity to generate AGE decreased rapidly during
the intraperitoneal dwell. In contrast AOPP, that is, the tive carbonyl compounds (GDP) might damage the peri-
toneal membrane.long-lived products of oxidative damage assessed as chlo-
ramine-T equivalents, increased rapidly [12]. The rapid Our observations on the deleterious potential of GDP
go beyond damage to the peritoneal membrane, how-generation of AOPP during short intraperitoneal dwells
presumably reflects high intraperitoneal oxidative stress, ever, and are even consistent with the possibility of sys-
temic effects following absorption of intraperitonealpossibly mediated by carbonyl compounds. The AGE
and AOPP measurements ex vivo, reflecting the capacity GDP (or compounds derived thereof). This finding is of
considerable concern. Uremic toxicity has recently beento glycate and oxidize, respectively, are analogous to the
carbonyl test proposed by Miyata et al [16]. ascribed, at least in part, to AGE formation [21]. A
contribution of the PD fluid to systemic accumulation ofCarbonyl compounds disappear during the intraperi-
toneal dwell and we wondered about the fate of these AGE, although relatively small in our short-term study,
therefore may not be negligible. This possibility was pre-compounds. We are aware of the limitations of the mea-
Zeier et al: Absorption of carbonyl compounds in peritoneal tissue 305
125 is locally produced in the peritoneal cavity during continuousviously entertained by other authors who speculated that
ambulatory peritoneal dialysis. Perit Dial Int 14:132–136, 1994
in addition to the carbonyl load resulting from uremia, 10. Visser CE, Brouwer-Steenbergen JJE, Betjes MGH, et al: Can-
cer antigen 125: A bulk marker for the mesothelial mass in stableglucose-derived reactive carbonyl compounds may be
peritoneal dialysis patients. Nephrol Dial Transplant 10:64–69, 1995involved in the functional alteration of the peritoneal
11. Nilsson-Thorell CB, Muscalu N, Andre´n A, et al: Heat steriliza-
membrane [22]. Furthermore, Witowski et al studied tion of fluids for peritoneal dialysis gives rise to aldehydes. Perit Dial
Int 13:208–213, 1993long-term human peritoneal mesothelial cell cultures and
12. Witko-Sarsat V, Friedlander M, Capeille`re-Blandin C, et al:noted that glucose degradation products impair viability,
Advanced oxidation protein products as a novel marker of oxida-
interleukin-6 (IL-6) secretion as well as fibronectin re- tive stress in uremia. Kidney Int 49:1304–1313, 1996
13. Pocock SJ: The analysis and interpretation of crossover trials, inlease [23].
Clinical Trials, Chichester, John Wiley & Sons, 1983, pp 114–119Finally, in a prospective randomized study, Jones et al
14. Kislinger T, Fu C, Huber B, et al: N(epsilon)-(carboxymethyl)lys-
documented that the addition of bicarbonate modulates ine adducts of proteins are ligands for receptor for advanced glyca-
tion end products that activate cell signaling pathways and modu-concentrations of putative markers of peritoneal mem-
late gene expression. J Biol Chem 274:31740–31749, 1999brane integrity and inflammation [24], a point that was
15. Hylander B, Granroth B, Wieslander A: CA 125 during the
not addressed in the present study. first 8 weeks of CAPD treatment: Influence of GDP. Perit Dial Int
21(Suppl 1):27, 2001In summary, our study results lend further support to
16. Miyata T, Horie K, Ueda Y, et al: Advanced glycation and lipidoxi-the postulate [25] that formation of GDP during steriliza-
dation of the peritoneal membrane: Respective roles of serum and
tion and storage of PD fluid should be avoided. peritoneal fluid reactive carbonyl compounds. Kidney Int 58:425–
435, 2000
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